

This was published 1 year ago

Proteomics on fast track to deliver simple endometriosis blood test

Brought to you by BULLS N' BEARS

James Pearson

May 26, 2025 — 5:04pm

ASX-listed diagnostics innovator Proteomics International Laboratories plans to start a commercial roll-out of its groundbreaking, simple “traffic light” diagnostic blood test for endometriosis within months, in the process revolutionising healthcare for the disease.

The company says its latest trial of its PromarkerEndo test has put it on a fast track to deliver the first clinically viable, real-world, non-invasive diagnostic test for a disease affecting one in nine women and girls and costing the Australian economy nearly \$10 billion.



Proteomics International groundbreaking, simple endometriosis blood test could revolutionise healthcare for the disease.

Over the weekend, Proteomics released the results of its latest trial, involving 704 blood plasma samples, to leading medical specialists and researchers at the prestigious World

Congress on Endometriosis in Sydney.

The trial used a diagnostic test consolidated from earlier prototype models to compare cases of endometriosis with general population controls and symptomatic patients. Proteomics said the trial delivered stunning accuracy in diagnosing cases across all stages of the debilitating disease.

‘This is a major step forward in making non-invasive endometriosis diagnosis a reality.’

Proteomics International Laboratories managing director Dr Richard Lipscombe

In a sector where a diagnosis has traditionally taken an average of seven years and involved a painful and invasive laparoscopy and tissue biopsy, this simple blood test is poised to flip the script entirely.

For the first time, doctors may soon swap the scalpel for a blood test, with PromarkerEndo positioned to become the frontline tool in detecting endometriosis in symptomatic patients. PromarkerEndo uses a universal “traffic light” risk score - low, moderate or high - to indicate a patient’s likelihood of having endometriosis. In validation trials, the test clocked an overall accuracy score of 0.92 and reached up to 98 per cent sensitivity in severe cases. It has a robust stage one accuracy performance of 89 per cent in early-stage disease, which is often the hardest to detect.

Proteomics International Laboratories managing director Dr Richard Lipscombe said:

“This is a major step forward in making non-invasive endometriosis diagnosis a reality. The advances support our commercialisation strategy and reinforce the potential for PromarkerEndo to become a standard part of the clinical diagnostic pathway.”

The company says the test is also being considered for use in women undergoing fertility treatments. Endometriosis is three times more common among IVF patients, where early intervention can be crucial. With fertility treatments on the rise globally, the commercial implications of PromarkerEndo could be significant.

Professor Peter Rogers, a leading endometriosis researcher at the Royal Women’s Hospital, said the test could transform patient management. “A reliable blood test that detects early-stage disease would allow us to intervene earlier, particularly in fertility cases where delays can have lasting consequences,” Professor Rogers said.

The commercial rollout of PromarkerEndo is now squarely in sight, with Proteomics targeting an Australian launch in the third quarter of this year.

The company plans to use its existing direct-to-consumer channels while also tapping into general practitioners and women's health specialists. Regulatory and clinical testing approvals are underway and patents are pending in all major jurisdictions.

PromarkerEndo now joins Proteomics International's expanding arsenal of precision diagnostics, all powered by its cutting-edge Promarker platform. The protein blood test is the same innovation behind the company's PromarkerD test for diabetic kidney disease and PromarkerEso for oesophageal cancer.

With PromarkerEndo now in the final stages of real-world validation and garnering backing from the scientific and medical communities, Proteomics is on the cusp of a commercial win. Beyond that, it could be on the verge of also changing patients' lives.

Is your ASX-listed company doing something interesting? Contact:

mattbirney@bullsnbears.com.au

MORE: [Bulls N' Bears](#) [Shares](#) [Sharemarket](#) [Proteomics International Laboratories](#) [Endometriosis](#)